Purpose of review: Prolonged suppression of plasma viremia is now achievable in a majority of HIV-infected individuals receiving antiretroviral therapy (ART). However, ART alone cannot eradicate HIV in infected individuals. The purpose of this review is to discuss the importance of tracking levels of infected CD4+ T cells carrying replication-competent HIV in basic and clinical research and how the use of this virologic marker could help determine the efficacy of ART and several novel therapeutic strategies that are being proposed for eliminating persistent viral reservoir in infected individuals receiving ART.
Recent findings: In recent years, there has been a growing interest within the HIV/AIDS scientific community to develop therapeutic strategies aimed at eliminating persistently infected CD4+ T cells in order to achieve a cure for HIV in infected individuals receiving ART. These approaches include administration of HIV-activating agents, modification of the genetics of CD4+ T cells, stem cell transplantation, and therapeutic vaccination. Such approaches would ultimately require careful and accurate assessments of the effect of therapeutic agents on HIV burden in infected individuals.
Summary: Given that the majority of infected CD4+ T cells in vivo carry replication-defective HIV, longitudinal measurements of the frequency of cells carrying replication-competent HIV along with other quantitative virologic parameters, such as levels of plasma viremia and cell-associated viral nucleic acid, can provide critical insight into the dynamics of the persistent viral reservoirs. Information related to HIV pathogenesis and the feasibility of eradicating the virus in infected individuals receiving ART in combination with novel therapeutic agents can also be gained from these analyses.
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Correspondence to Tae-Wook Chun, PhD, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 6A32, 9000 Rockville Pike, Bethesda, MD 20892, USA. Tel: +1 301 496 0890; fax: +1 301 402 5920; e-mail: email@example.com
Antiretroviral therapy (ART) suppresses HIV plasma viremia to below the limit of detection in the vast majority of infected individuals. As a result, ART reduces morbidity and mortality in HIV-infected individuals as well as the likelihood of transmitting the virus to uninfected individuals [1–6]. However, it has not been possible to eradicate HIV by ART alone, likely in part due to the persistence of various viral reservoirs in the blood and tissue compartments of infected individuals [7▪▪–9▪▪]. In addition, it has been repeatedly demonstrated that plasma viremia rapidly rebounds in virtually all HIV-infected individuals upon discontinuation of ART regardless of the duration and timing of therapy [10–14]. Consequently, there is a growing interest in developing alternative therapies to eliminate persistent HIV reservoirs and/or to harness host immunity against the virus in order to control viral replication upon discontinuation of ART [15–18]. Currently, suppression of plasma viremia to below the limit of detection by standard assays is a primary goal in the management of HIV infection . Several US Food and Drug Administration (FDA)-approved plasma viral load assays are widely being used to monitor the level of HIV replication and virologic responses to ART in infected individuals . However, other laboratory-based virologic assays are also commonly being used in basic and clinical laboratories to measure HIV burden in clinical specimens obtained from infected individuals, including from those who have achieved maximal suppression of plasma viremia (typically <20–50 copies of HIV RNA/ml) by ART . These laboratory assays are typically PCR-based methods that are designed to quantify the level of cell-associated HIV DNA (total, integrated, and episomal) [22,23] and HIV RNA (unspliced and multiply spliced) . Although these assays provide helpful information with regards to the frequency of cells carrying HIV and the degree and extent of viral replication infected individuals, they cannot distinguish between cells carrying infectious HIV and those harboring defective virus. For this reason, assays capable of detecting replication-competent HIV were developed more than two decades ago and have since been widely used to measure the level of cells carrying infectious virus in HIV-infected individuals [25–27]. This review discusses various methodologies used for detecting replication-competent virus and how such assays are being utilized in basic and clinical research to address the pathogenesis of HIV infection, the persistence of viral reservoirs, and new therapeutic strategies aimed at eradicating the virus in infected individuals receiving ART.
THE INS AND OUTS OF QUANTITATIVE COCULTURE ASSAY
Determining the frequency of cells carrying replication-competent virus in HIV-infected individuals is typically achieved by conducting a quantitative coculture assay [27,28]. This assay is comprised of three major components. First, bulk or subsets of CD4+ T cells are isolated from the peripheral blood mononuclear cells (PBMCs) of infected individuals via blood draw or leukapheresis. Typically, infectious HIV can be detected from a relatively small number of CD4+ T cells (1–2 × 106) in viremic individuals (>50 copies of HIV RNA/ml plasma) or in individuals who have received ART for relatively short periods of time (<1 year). However, a substantially higher number of purified CD4+ T cells are required to detect infectious HIV in individuals who have received ART for more than 5 years and those who initiated therapy during the early/acute phase of infection. Enrichment of bulk or subsets of CD4+ T cells (such as resting CD4+ T cells) is typically achieved by using one of the many commercially available cell enrichment kits that yield high levels of purity (>95–99%). Second, highly enriched CD4+ T cells are accurately enumerated, preferably using an automated cell counter, followed by placing the cells in culture using a limiting dilution approach (five-fold dilutions starting from 1 × 106 cells down to 320 cells per well in duplicate) [26,27] and/or culturing replicates of 5–10 × 106 cells [28,29]. The cell cultures are then maximally stimulated for viral production with irradiated PBMCs from healthy HIV-negative donors in the presence of either phytohaemagglutinin or anti-CD3 antibody for 24 h. In order to further propagate the virus produced by the CD4+ T cells from HIV-infected individuals, anti-CD3-stimulated, CD8-depleted PBMCs from healthy HIV-negative donors are added to the culture on days 1 and 7 followed by periodic removal of cells and replenishment of fresh culture medium containing interleukin (IL)-2. The cultures are typically maintained for 14–21 days. Finally, HIV-positive wells are identified by HIV p24 ELISA and infectious units per million cells are determined by a maximum likelihood method .
MONITORING INFECTIOUS HIV BURDEN IN THE ERA OF ANTIRETROVIRAL THERAPY
The qualitative and quantitative assays for detecting replication-competent HIV were first performed on unfractionated PBMCs without enrichment of CD4+ T cells [25,30]. Given that CD8+ T cells suppress HIV replication , especially in the coculture setting , a more sensitive assay was then developed in which CD4+ T cells from HIV-infected individuals were enriched to a high purity . This modified quantitative coculture assay was subsequently instrumental to identify and characterize latently infected, resting CD4+ T cells in HIV-infected viremic individuals . This study also provided important insight into the virologic aspects of infected CD4+ T cells by demonstrating that the vast majority of resting CD4+ T cells carrying HIV proviral DNA was replication-defective . In addition, the data from this study suggested that the total body viral burden of the latent viral reservoir carrying replication-competent HIV was very small (generally <0.1% of resting CD4+ T cells) and that such infected cells could be long-lived, may not be recognized by the host immune system, and may resist virus-induced cytopathic effects .
Shortly after the introduction of clinically effective ART, several studies that applied mathematical modeling to investigate the kinetics of plasma viremia and to predict the half-lives of the virus in infected individuals following ART generated considerable optimism that HIV could be eradicated in such individuals after 2–3 years of therapy . However, in 1997, three independent studies involving cohorts of HIV-infected individuals receiving effective ART used quantitative coculture assays to demonstrate that the latent viral reservoir carrying replication-competent HIV persisted in virtually all individuals studied, casting serious doubt on the possibility of eradicating virus by ART alone [7▪▪–9▪▪]. Having clearly established that CD4+ T cells carrying infectious HIV persisted in infected individuals receiving ART despite sustained suppression of plasma viremia, many studies since have made use of the quantitative coculture assay to detect and monitor levels of infected CD4+ T cells carrying infectious HIV. Notably, this assay was used in a number of longitudinal studies where the objectives were to determine the half-life of infectious latent viral reservoirs and to project the duration of ART that would be required for eliminating these cells in HIV-infected individuals receiving ART. Two longitudinal studies that primarily focused on a cohort of HIV-infected individuals who began ART during the chronic phase of infection suggested that the half-life of the latent viral reservoir carrying replication-competent virus was greater than 44 months and that even a duration of therapy exceeding 60 years may not be sufficient to completely eradicate HIV [34▪▪,35]. However, two other studies demonstrated that the half-life of the latent viral reservoir was substantially shorter (4–6 months) in HIV-infected individuals who initiated ART during the acute/early phase of infection. These studies projected that at least 7–8 years of continuous therapy would be required to eradicate HIV; however, these estimates were based on the assumptions that ART was capable of completely shutting down viral replication and that no other viral reservoirs existed in infected individuals receiving ART [36,37]. Of note, one of the above studies used a modified version of the quantitative coculture assay (along with a conventional assay) in which replicates of 10 × 106 CD4+ T cells were used to evaluate the infectious HIV burden . Despite sharp contrasts between estimated half-lives of the latent viral reservoir reported in the above studies, the general consensus in the field is that this pool of infected cells is unlikely to be eliminated by ART alone and remains a major impediment to the eradication of the virus in infected individuals receiving ART.
Quantitation of HIV-infected CD4+ T cells carrying replication-competent virus may also be very helpful in delineating the efficacy of therapeutic strategies aimed at eliminating persistent HIV reservoirs and/or obtaining a cure for the virus in infected individuals receiving ART. Over a decade ago, one study demonstrated a marked diminution of the size of the pool of latently infected, resting CD4+ T cells carrying infectious HIV in infected individuals receiving ART and repeated cycles of intermittent IL-2 compared to those who received ART alone . More recently, a number of novel therapeutic strategies aimed at achieving the eradication of HIV in infected individuals receiving clinically effective ART have been suggested and several are currently under investigation [15,16]. Among these is valproic acid (VPA), a histone deacetylase (HDAC) inhibitor that was first tested in vitro and ex vivo as a potential agent for purging the latent HIV reservoir . Subsequently, in an in-vivo study that evaluated the HIV burden at two time points using a quantitative coculture assay, a reduction in the latent viral reservoir was observed in a small number of infected individuals receiving ART and VPA [39▪]. However, a number of follow-up studies demonstrated that VPA did not lower the frequency of resting CD4+ T cells carrying infectious HIV more than ART alone [40–42,43▪▪]. More potent HDAC inhibitors, such as suberoylanilide hydroxamic acid [44▪▪], are currently being investigated in several clinical trials as potential virus-purging agents.
The detection of replication-competent HIV by large-scale (i.e. replicates of >5–10 × 106 CD4+ T cells) quantitative coculture assays could potentially help assess the impact of other cure-related therapeutic strategies. In this regard, a number of anecdotal clinical cases have been recently described in which the burden of HIV DNA was reduced to an undetectable level following chemotherapy and stem cell transplantation [45▪▪,46▪▪]. These cases and their impact in the area of HIV eradiation would greatly benefit from the examination of the persistent HIV reservoirs carrying replication-competent virus by conducing quantitative coculture assays on the largest possible number of purified CD4+ T cells. Such quantitative coculture assays that can probe a much greater proportion of infected CD4+ T cells compared to molecular assays would go a long way to understanding the fate of the persistent HIV reservoirs under conditions that are thought to greatly diminish the HIV burden. In addition, the use of a quantitative coculture assay in cure-related studies provides an important advantage over PCR-based molecular assays in that the vast majority of infected CD4+ T cells carrying HIV proviral DNA are noninfectious and as such these molecular approaches may not adequately evaluate the efficacy of novel therapeutic agents in terms of lowering the viral burden.
ADVANTAGES AND DISADVANTAGES OF QUANTITATIVE MEASUREMENTS OF INFECTIOUS HIV OVER OTHER VIROLOGIC METHODS
The quantitative coculture assay provides a unique opportunity to monitor the frequency of cells that could potentially give rise to infectious HIV in infected individuals. Although highly sensitive PCR-based assays can accurately measure the level of cell-associated viral DNA (total, integrated, and episomal) and cell-associated HIV RNA (spliced and unspliced) in the PBMCs and lymphoid tissues of infected individuals, these methods cannot distinguish between cells carrying replication-competent virus from those harboring replication-defective HIV. Given that less than 1% of infected CD4+ T cells carrying HIV DNA are capable of producing replication-competent virus , it is necessary to utilize a method, such as the quantitative coculture assay, to measure the infectious HIV burden. In addition, the quantitative coculture assay (when configured to evaluate replicates of 5–10 × 106 cells per well) allows the examination of large numbers of cells (i.e. >100 × 106 CD4+ T cells) from infected individuals receiving ART [28,29]. This is especially helpful if a study participant has an exceptionally low level of cell-associated HIV DNA or RNA in CD4+ T cells [47▪] because a typical PCR can only accommodate a small amount of nucleic acid (105–106 cell equivalent) per reaction.
There are also several disadvantages/limitations of the quantitative coculture assay when compared to other virologic assays, including PCR-based molecular assays. First, the reproducibility and sensitivity of the quantitative coculture assay remain to be fully delineated. The confidence intervals for individual measurements involving serially diluted CD4+ T cells (1 × 106 to 320 cells per well in duplicate) are estimated to be relatively wide, at approximately ±0.7 log infectious units per million cells [34▪▪]. On the contrary, most, if not all, PCR-based molecular assays specific for HIV have single copy sensitivity. Of note, laboratory-based plasma viral load assays are now capable of detecting 1–2 copies of HIV RNA per ml of plasma in infected individuals receiving ART [48,49,50▪]. Second, depending on clinical history, the assay may require the purification of large numbers of CD4+ T cells from infected donors [47▪]. It is often necessary to obtain leukapheresis products (>200 × 106 PBMCs) in order to detect infectious HIV in study participants who have been receiving ART for extended periods [51,52]. Such assay requirements increase costs and are labor intensive. Third, the assay detects infectious HIV originating from cells that carry either integrated or unintegrated proviral DNA but cannot distinguish between the two forms and thus is a limitation when trying to establish the source of replication-competent virus. Fourth, the precise association between quantitative coculture assay measurements and other virologic markers remain to be delineated. Finally, the clinical relevance of the level of infected CD4+ T cells carrying infectious HIV remains to be determined in vivo.
Despite more than a decade of intense research and recent therapeutic advances, achieving a true eradication of HIV remains a daunting challenge for the HIV/AIDS scientific community [15–18]. It is estimated that one in 106–109 CD4+ T cells carries replication-competent HIV in infected individuals receiving clinically effective ART [34▪▪,35,47▪,51]. Despite such low frequencies, the presence of persistently infected CD4+ T cells is one of the major impediments to eradicating HIV in infected individuals receiving ART and in whom sustained suppression of plasma viremia has been achieved for prolonged periods [15–18]. Consequently, careful monitoring of the frequency of CD4+ T cells carrying infectious virus is likely to remain an essential element of current and future viral reservoir research efforts. In this regard, a major thrust of current HIV therapeutic research is the development of clinical strategies aimed at eliminating persistent viral reservoirs with the ultimate goal being to eradicate the virus. Therefore, quantitative laboratory assays that precisely measure the number of infected CD4+ T cells carrying replication-competent HIV are likely to play a crucial role in determining the efficacy of therapeutic agents that are designed to either directly target HIV reservoirs or reduce them by enhancing the host immune system. Finally, considerable efforts should be made within the HIV/AIDS scientific community to develop new or improved existing assays for evaluating levels of infectious HIV that are reproducible, clinically relevant, and amenable to high-throughput technologies.
This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Conflicts of interest
The author has declared that no competing interests exist.
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
▪ of special interest
▪▪ of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 157).
1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–29.
3. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11–19.
4. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293–299.
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092–2098.
6. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376:49–62.
7▪▪. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193–13197.
This study reported that the latent viral reservoir carrying replication-competent HIV persists in infected individuals receiving ART for up to three years.
8▪▪. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295–1300.
This study reported that the latent viral reservoir carrying replication-competent HIV persists in infected individuals receiving ART for up to 3 years.
9▪▪. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291–1295.
This study reported that the latent viral reservoir carrying replication-competent HIV persists in infected individuals receiving ART for up to 3 years.
10. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109–15114.
11. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999; 13:677–683.
12. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999; 13:F59–62.
13. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79–86.
14. Chun TW, Davey RT Jr, Engel D, et al. Re-emergence of HIV after stopping therapy. Nature 1999; 401:874–875.
15. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304–1307.
16. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174–180.
17. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS 2012; 26:1261–1268.
18. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607–614.
19. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. Jama 2012; 308:387–402.
20. Cobb BR, Vaks JE, Do T, Vilchez RA. Evolution in the sensitivity of quantitative HIV-1 viral load tests. J Clin Virol 2011; 52 (Suppl 1):S77–S82.
21. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011; 25:885–897.
22. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284–1290.
23. Mexas AM, Graf EH, Pace MJ, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 2012; 26:2295–2306.
24. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614–1622.
25. ACTG Laboratory Technologist Committee. HIV qualitative PBMC macrococulture assay. ACTG Laboratory Manual 2004, Version 2.0.
26. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32:732–739.
27. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183–188.
28. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3–15.
29. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nat Med 1999; 5:651–655.
30. Dimitrov DH, Melnick JL, Hollinger FB. Microculture assay for isolation of human immunodeficiency virus type 1 and for titration of infected peripheral blood mononuclear cells. J Clin Microbiol 1990; 28:734–737.
31. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563–1566.
32. Chun TW, Justement JS, Moir S, et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci U S A 2001; 98:253–258.
33. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188–191.
34▪▪. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512–517.
This is the first study that measured the half-life of the latent HIV reservoir in infected individuals receiving ART. The authors conducted extensive longitudinal measurements of the frequency of resting CD4+ T cells carrying infectious HIV and demonstrated that the half-life of the latent viral reservoir is extremely long (>40 months).
35. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727–728.
36. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605–1613.
37. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762–1764.
38. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 2011; 6:25–29.
39▪. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549–555.
This article describes the effect of virus purging agent, valproic acid, on the level of resting CD4+ T cells carrying replication-competent HIV in infected individuals receiving ART.
40. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833–836.
41. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125–1129.
42. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22:1131–1135.
43▪▪. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 2012; 13:291–296.
This article demonstrated that valproic acid does not eliminate latently infected, CD4+ T cells in infected individuals receiving ART.
44▪▪. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482–485.
This article describes the effect of virus purging agent, SAHA, on the level cell-associated HIV RNA in resting CD4+ T cells of infected individuals receiving ART.
45▪▪. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692–698.
This study describes a case report of an HIV-infected individual who may have achieved a ‘functional’ cure after receiving repeated cycles of chemotherapy and stem cell transplantation from a donor lacking expression of CCR5.
46▪▪. Henrich T, Sciaranghella G, Li J, et al.
Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation in two HIV-positive individuals. XIX International AIDS Conference 2012, Washington, DC.
This abstract describes two HIV-infected individuals who may have achieved a ‘functional’ cure after receiving chemotherapy and allogeneic stem cell transplantation from uninfected healthy donors.
47▪. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24:2803–2808.
This study describes a case report of an HIV-infected individual who had achieved an extraordinarily low level of infectious HIV burden and experienced delayed plasma viral rebound upon cessation of ART.
48. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531–4536.
49. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathogens 2007; 3:e46.
50▪. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879–3884.
The authors of this article reported that low levels of plasma viremia (1–49 copies of HIV RNA per ml) persist in the majority of HIV-infected individuals receiving clinically effective ART.
51. Chun TW, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250–3255.
52. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135–138.